$1.61
-0.005-0.31%
Last update: 10:57 AM
15 minutes delayed
Lyell Immunopharma
LYELNASDAQ
want to know what
the Bulls & Bears Say?
Lyell Immunopharma (NASDAQ:LYEL) Stock, Analyst Ratings, Price Targets, Forecasts
Lyell Immunopharma Inc has a consensus price target of $6.33 based on the ratings of 19 analysis. The 3 most-recent analyst ratings were released by B of A Securities, HC Wainwright & Co., and HC Wainwright & Co. on June 27, 2024, June 27, 2024, and May 7, 2024, respectively. With an average price target of $4.33 between B of A Securities, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 167.49% upside for Lyell Immunopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
HC Wainwright & Co.
JP Morgan
Morgan Stanley
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Lyell Immunopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 270.37% | B of A Securities | Geoff Meacham | $9 → $6 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | -38.27% | HC Wainwright & Co. | Mitchell Kapoor | $6 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Mitchell Kapoor | → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Mitchell Kapoor | $8 → $6 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | 393.83% | HC Wainwright & Co. | Mitchell Kapoor | $9 → $8 | Maintains | Buy | Get Alert |
| 08/28/2023 | Buy Now | 208.64% | JP Morgan | Eric Joseph | $15 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 05/05/2023 | Buy Now | 455.56% | HC Wainwright & Co. | Mitchell Kapoor | → $9 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 455.56% | HC Wainwright & Co. | Mitchell Kapoor | $11 → $9 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | 146.91% | Morgan Stanley | Matthew Harrison | $7 → $4 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 332.1% | Morgan Stanley | Matthew Harrison | $15 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/11/2022 | Buy Now | — | Goldman Sachs | Salveen Richter | — | Downgrade | Buy → Neutral | Get Alert |
| 10/17/2022 | Buy Now | 640.74% | HC Wainwright & Co. | Mitchell Kapoor | → $12 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 640.74% | Goldman Sachs | Salveen Richter | $21 → $12 | Maintains | Buy | Get Alert |
| 03/31/2022 | Buy Now | 1196.3% | Goldman Sachs | Salveen Richter | $31 → $21 | Maintains | Buy | Get Alert |
| 01/06/2022 | Buy Now | 1134.57% | Morgan Stanley | Matthew Harrison | $25 → $20 | Maintains | Overweight | Get Alert |
| 07/12/2021 | Buy Now | 1443.21% | Morgan Stanley | Matthew Harrison | — | Initiates | → Overweight | Get Alert |
| 07/12/2021 | Buy Now | 1443.21% | B of A Securities | Geoff Meacham | — | Initiates | → Buy | Get Alert |
| 07/12/2021 | Buy Now | 1258.02% | JP Morgan | — | — | Initiates | → Overweight | Get Alert |
| 07/12/2021 | Buy Now | 1751.85% | Goldman Sachs | Salveen Richter | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Lyell Immunopharma (LYEL) stock?
The latest price target for Lyell Immunopharma (NASDAQ:LYEL) was reported by B of A Securities on June 27, 2024. The analyst firm set a price target for $6.00 expecting LYEL to rise to within 12 months (a possible 271.52% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
The latest analyst rating for Lyell Immunopharma (NASDAQ:LYEL) was provided by B of A Securities, and Lyell Immunopharma maintained their buy rating.
When was the last upgrade for Lyell Immunopharma (LYEL)?
There is no last upgrade for Lyell Immunopharma
When was the last downgrade for Lyell Immunopharma (LYEL)?
The last downgrade for Lyell Immunopharma Inc happened on June 27, 2024 when HC Wainwright & Co. changed their price target from $6 to $1 for Lyell Immunopharma Inc.
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a maintained with a price target of $9.00 to $6.00. The current price Lyell Immunopharma (LYEL) is trading at is $1.62, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.